Prognosis
U.S. Restricts Lilly Antibody Orders in 3 States on Mutant Worry
- Drug’s efficacy against California variant may be impaired
- Recommendations on bamlanivimab are under consideration
Photographer: David Paul Morris/Bloomberg
This article is for subscribers only.
U.S. health officials have restricted orders of Eli Lilly and Co.’s single-antibody therapy in three states on concerns about efficacy against a new coronavirus variant identified in California earlier this year.
The limit on Lilly’s bamlanivimab affects California, Arizona and Nevada, the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response said Thursday in a statement. Government officials are continuing to study whether to recommend the drug in areas where the variant, called CAL.20C, is prevalent.